The trial was based on the assumption of endogenous vaccination acting through repeated waves of rituximab-induced lymphoma cell killing, followed by the Fc-receptor-mediated uptake of tumor-associated antigens by IFN-DC exploiting drug-induction of tumor cell death with release of tumor-associated antigens. The gene discussed is IFNA1; the disease is lymphoma.